ReviewPatient preference and adherence2016

Polifeprosan 20, 3.85% carmustine slow release wafer in malignant glioma: patient selection and perspectives on a low-burden therapy.

Lawrence KleinbergPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.